News

Buschbeck Lab 2021

Researchers at the Josep Carreras Institute find inhibition of CBP/p300 may enhance sensitivity of MDS cells to azacytidine

Scientists at the Josep Carreras Leukaemia Research Institute have found that it is possible to enhance the antitumor activity of azacytidine, one of the most common treatment option for patients with high-risk myelodysplastic syndrome, by inhibiting the CBP and p300 proteins. This finding opens the door to synergistically fight these kind of cancers, especially in patients at risk of developing acute myeloid leukemia.

Read more
informe REDECAN 2021

REDECAN publishes the latest data on the incidence of hematological neoplasms in Spain

Dr. Rafael Marcos-Gragera, member of the Josep Carreras Leukaemia Research Institute and leader of the Girona Cancer Registry group of the Institut Català d'Oncologia / Pla director d'oncologia, has coordinated the report published by the Spanish Network of Cancer Registries (REDECAN) on the incidence of hematological neoplasms that predicts the diagnosis of 26,000 new cases in 2021. 

Read more
sanchez-céspedes group

New insights on the role of the MAX protein in lung cancer

A team of scientists led by Dr. Montse Sanchez-Cespedes, group leader at the Josep Carreras Leukaemia Research Institute, test the characteristics and the tumour suppressor function of MAX and its role in the development of small cell lung cancer, a very aggressive type of lung cancerResults show that the cancer cells lacking MAX have neuroendocrine (ASLC1- or NEUROD1-type) characteristics and that their oncogenic capability is independent of the MYC oncogene, involving an abnormal function of the ncPRC1.6 repressive complex. 

Read more